Read by QxMD icon Read

icc hcc

Kunio Mochizuki, Masataka Kawai, Toru Odate, Ippei Tahara, Tomohiro Inoue, Kazunari Kasai, Tadao Nakazawa, Tetsuo Kondo
BACKGROUND/AIM: Switch/sucrose non-fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also named integrase interactor 1, is one of the core subunit proteins in the SWI/SNF ATP-dependent chromatin remodeling complex encoded at chromosomal position 22q11.2. Complete loss of SMARCB1 expression has been reported in various malignant tumors. Immunohistochemistry has demonstrated that SMARCB1 mutation/inactivation correlates well with loss of nuclear SMARCB1 expression...
December 2018: Anticancer Research
Kyohei Yugawa, Tomoharu Yoshizumi, Yohei Mano, Noboru Harada, Shinji Itoh, Toru Ikegami, Yuji Soejima, Nobuhiro Fujita, Kenichi Kohashi, Shinichi Aishima, Yoshinao Oda, Masaki Mori
BACKGROUND: Hepatic carcinosarcomas, which include both carcinomatous and sarcomatous elements, are uncommon in adults. Although carcinosarcoma in hepatocellular carcinoma is occasionally reported, carcinosarcoma in intrahepatic cholangiocarcinoma (ICC) is an extremely rare ICC variant. Few such cases have been reported in English and no large study of its clinicopathological features exists. CASE PRESENTATION: Here, we report a 60-year-old man with an asymptomatic hepatic B infection who developed hepatic carcinosarcoma from an otherwise normal liver...
November 26, 2018: Surgical Case Reports
Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Masafumi Ohira, Koichi Kato, Yuki Fujii, Ko Sugiyama, Naoki Okada, Takanori Ohata, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Akinobu Taketomi
BACKGROUND AND AIM: Combined hepatocellular-cholangiocarcinoma (CHC) is a primary liver cancer containing both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) elements. Its reported clinicopathological features and prognoses have varied because of its low prevalence. This study aimed to clarify these aspects of CHC. METHODS: We enrolled 28 patients with CHC, 1050 with HCC, and 100 with ICC and compared the clinicopathological characteristics and prognosis of CHC with HCC and ICC...
November 21, 2018: Journal of Gastroenterology and Hepatology
Zi-Xiang Kuai, Xi-Qiao Sang, Yuan-Fei Yao, Chun-Yu Chu, Yue-Min Zhu
BACKGROUND: Non-monoexponential diffusion models are being used increasingly for the characterization and curative effect evaluation of hepatocellular carcinoma (HCC). But the fitting quality of the models and the repeatability of their parameters have not been assessed for HCC. PURPOSE: To evaluate kurtosis, stretched exponential, and statistical models for diffusion-weighted imaging (DWI) of HCC, using b-values up to 2000 s/mm2 , in terms of fitting quality and repeatability...
November 16, 2018: Journal of Magnetic Resonance Imaging: JMRI
Daniel R Waisberg, Rafael S Pinheiro, Lucas S Nacif, Vinicius Rocha-Santos, Rodrigo B Martino, Rubens M Arantes, Liliana Ducatti, Quirino Lai, Wellington Andraus, Luiz C D'Albuquerque
Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent primary liver neoplasm after hepatocellular carcinoma (HCC), corresponding to 10% to 15% of cases. Pathologies that cause chronic biliary inflammation and bile stasis are known predisposing factors for development of ICC. The incidence and cancer-related mortality of ICC is increasing worldwide. Most patients remain asymptomatic until advance stage, commonly presenting with a liver mass incidentally diagnosed. The only potentially curative treatment available for ICC is surgical resection...
2018: Translational Gastroenterology and Hepatology
Dongli Shi, Liang Ma, Dawei Zhao, Jing Chang, Chen Shao, Shi Qi, Feng Chen, Yunfang Li, Xing Wang, Yanyan Zhang, Jing Zhao, Hongjun Li
BACKGROUND: Primary hepatic sarcomatous carcinoma (PHSC) is a rare malignancy composed of both carcinomatous (either hepatocellular or cholangiocellular) and sarcomatous components. The purpose of our study was to evaluate the imaging and clinical findings of PHSCs, improving the understanding and diagnosis of tumors. METHODS: We retrospectively reviewed the imaging and clinical findings of ten patients with pathologically proven PHSCs, including two cases of sarcomatous intrahepatic cholangiocarcinoma (S-ICC), seven cases of sarcomatous hepatocellular carcinoma (S-HCC) and one case of sarcomatous combined hepatocellular and cholangiocarcinoma (S-HCC-CC)...
October 12, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
Seung Kak Shin, Duck Joo Choi, Ju Hyun Kim, Yun Soo Kim, Oh Sang Kwon
Contrast-enhanced ultrasound (CEUS) is highly accurate in depicting the vascularity of liver nodules. The aim of this study was to verify the characteristics of CEUS in distinguishing small (≤3 cm) hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC).A total of 65 patients with a liver nodule (HCC, n = 58; ICC, n = 7) smaller than 3 cm who underwent liver CEUS and pathologic confirmation were retrospectively reviewed. CEUS findings were compared with histopathologic and clinical data...
October 2018: Medicine (Baltimore)
Edward C Lo, Adam N Rucker, Michael P Federle
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) comprise the majority of primary liver cancers. Both HCC and ICC have characteristic imaging appearances on multiphase computed tomography (CT) and magnetic resonance imaging (MRI). Several locoregional therapies, including radiation therapy, are used to treat unresectable disease and residual or recurrent tumor. The tumor response following locoregional therapies has variable imaging manifestations. Focal liver reaction, the imaging changes of the liver following radiation treatment, should be recognized and not mistaken for tumor...
October 2018: Seminars in Radiation Oncology
Jing Xu, Yanhong Tan, Xiaoxia Shao, Cuiming Zhang, Yanling He, Jie Wang, Yanfeng Xi
BACKGROUND: Intrahepatic cholangiocarcinomas (ICCs) are primary liver malignancies and are the second most common type of malignancy after hepatocellular carcinoma. ICCs are heterogeneous in clinical features, genotype, and biological behavior, suggesting that ICCs can initiate in different cell lineages. AIM: We investigated intrahepatic cholangiocarcinoma RBE cell lines for the markers neural cell adhesion molecule (NCAM) and c-Kit, which possess hepatic progenitor cells properties...
September 13, 2018: Pathology, Research and Practice
Jianping Xiong, Xin Lu, Weiyu Xu, Yi Bai, Hanchun Huang, Jin Bian, Lei Zhang, Junyu Long, Yiyao Xu, Zhenjie Wang, Haitao Zhao
Background: Metabolic syndrome is regarded as a risk factor for hepatocellular carcinoma. However, no research has been conducted to investigate the association between metabolic syndrome and cholangiocarcinoma (CCA), especially in the Chinese population. Herein, a hospital-based case-control study was carried out in China to explore the association between metabolic syndrome and CCA risk. Patients and methods: In this study, 303 CCA patients (136 intrahepatic cholangiocarcinoma [ICC] and 167 extrahepatic cholangiocarcinoma [ECC]) were included, who were observed at Peking Union Medical College Hospital (PUMCH), from 2002 to 2014...
2018: Cancer Management and Research
Xianlun Zou, Yan Luo, Zhen Li, Yao Hu, Haojie Li, Hao Tang, Yaqi Shen, Daoyu Hu, Ihab R Kamel
BACKGROUND: Accurate differentiation between intrahepatic mass-forming cholangiocarcinoma (IMCC) and hepatocellular carcinoma (HCC) is needed because treatment and prognosis differ significantly. PURPOSE: To explore whether volumetric apparent diffusion coefficient (ADC) histogram analysis can provide additional value to dynamic enhanced MRI in differentiating IMCC from HCC. STUDY TYPE: Retrospective. POPULATION: In all, 131 patients with pathologically proven IMCC (n = 33) or HCC (n = 98)...
September 12, 2018: Journal of Magnetic Resonance Imaging: JMRI
(no author information available yet)
The hepatic microenvironment epigenetically directs lineage commitment to promote ICC or HCC liver tumors.
November 2018: Cancer Discovery
Jordi Rimola, Matthew S Davenport, Peter S Liu, Theodore Brown, Jorge A Marrero, Barbara J McKenna, Hero K Hussain
PURPOSE: To compare the diagnostic accuracy of extracellular gadolinium-based contrast-enhanced MRI (Gd-MRI) and gadoxetic acid-enhanced MRI (EOB-MRI) for the assessment of hepatocellular carcinoma (HCC) response to locoregional therapy (LRT) using explant correlation as the reference standard. METHODS: Forty-nine subjects with cirrhosis and HCC treated with LRT who underwent liver MRI using either Gd-MRI (n = 26) or EOB-MRI (n = 23) within 90 days of liver transplantation were included...
September 14, 2018: Abdominal Radiology
Liang Zhang, Na Wang, Jingsong Mao, Xiaofei Liu, Zhichun Gao, Xu Dai, Bo Feng
PURPOSE: To evaluate whether changes in volumetric iodine concentration (VIC) could serve as a suitable predictor of therapeutic response to microwave (MW) ablation in a rabbit intrahepatic VX2 tumor model. MATERIALS AND METHODS: Sixteen intrahepatic VX2 tumors were transplanted in 8 New Zealand White rabbits treated with MW ablation. Contrast-enhanced dual-energy CT scans were obtained at baseline and follow-up. Therapeutic response assessment by modified Response Evaluation Criteria In Solid Tumors (mRECIST), Choi criteria, and VIC changes was performed...
September 11, 2018: Journal of Vascular and Interventional Radiology: JVIR
Adianto Nugroho, Kwang-Woong Lee, Kyung-Bun Lee, Hyo-Shin Kim, Hyeyoung Kim, Nam-Joon Yi, Kyung-Suk Suh
The incidence of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) in a single patient accounts for only 0.4 to 14% of all primary liver cancer. However, the prognosis of its intrahepatic cholangiocarcinoma (ICC) component is poor. We experienced a unique case of a sequentially developed cHCC-CC with adrenal metastasis as the primary presentation and a hidden primary hepatocellular carcinoma. A 65-year-old female with a history of jaundice and abdominal discomfort was diagnosed with S4 ICC measuring 5 cm in diameter, and characterized histologically as papillary adenocarcinoma with intraductal growth, but without any evidence of malignant hepatocyte...
August 2018: Annals of Hepato-Biliary-Pancreatic Surgery
Marco Seehawer, Florian Heinzmann, Luana D'Artista, Jule Harbig, Pierre-François Roux, Lisa Hoenicke, Hien Dang, Sabrina Klotz, Lucas Robinson, Grégory Doré, Nir Rozenblum, Tae-Won Kang, Rishabh Chawla, Thorsten Buch, Mihael Vucur, Mareike Roth, Johannes Zuber, Tom Luedde, Bence Sipos, Thomas Longerich, Mathias Heikenwälder, Xin Wei Wang, Oliver Bischof, Lars Zender
Primary liver cancer represents a major health problem. It comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), which differ markedly with regards to their morphology, metastatic potential and responses to therapy. However, the regulatory molecules and tissue context that commit transformed hepatic cells towards HCC or ICC are largely unknown. Here we show that the hepatic microenvironment epigenetically shapes lineage commitment in mosaic mouse models of liver tumorigenesis. Whereas a necroptosis-associated hepatic cytokine microenvironment determines ICC outgrowth from oncogenically transformed hepatocytes, hepatocytes containing identical oncogenic drivers give rise to HCC if they are surrounded by apoptotic hepatocytes...
October 2018: Nature
Li-Da Chen, Si-Min Ruan, Jin-Yu Liang, Zheng Yang, Shun-Li Shen, Yang Huang, Wei Li, Zhu Wang, Xiao-Yan Xie, Ming-De Lu, Ming Kuang, Wei Wang
AIM: To develop a contrast-enhanced ultrasound (CEUS) predictive model for distinguishing intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC) in high-risk patients. METHODS: This retrospective study consisted of 88 consecutive high-risk patients with ICC and 88 high-risk patients with HCC selected by propensity score matching between May 2004 and July 2016. Patients were assigned to two groups, namely, a training set and validation set, at a 1:1 ratio...
September 7, 2018: World Journal of Gastroenterology: WJG
Jessica L Petrick, Jake E Thistle, Anne Zeleniuch-Jacquotte, Xuehong Zhang, Jean Wactawski-Wende, Alison L Van Dyke, Meir J Stampfer, Rashmi Sinha, Howard D Sesso, Catherine Schairer, Lynn Rosenberg, Thomas E Rohan, Kim Robien, Mark P Purdue, Jenny N Poynter, Julie R Palmer, Christina C Newton, Martha S Linet, Linda M Liao, I-Min Lee, Jill Koshiol, Cari M Kitahara, Jonathan N Hofmann, Barry I Graubard, Edward Giovannucci, J Michael Gaziano, Susan M Gapstur, Neal D Freedman, Dawn Q Chong, Andrew T Chan, Julie E Buring, Laura E Beane Freeman, Peter T Campbell, Katherine A McGlynn
OBJECTIVE: Obesity and diabetes are associated with an increased liver cancer risk. However, most studies have examined all primary liver cancers or hepatocellular carcinoma, with few studies evaluating intrahepatic cholangiocarcinoma (ICC), the second most common type of liver cancer. Thus, we examined the association between obesity and diabetes and ICC risk in a pooled analysis and conducted a systematic review/meta-analysis of the literature. DESIGN: For the pooled analysis, we utilized the Liver Cancer Pooling Project, a consortium of 13 US-based, prospective cohort studies with data from 1,541,143 individuals (ICC cases n = 414)...
October 2018: American Journal of Gastroenterology
Meng-Shin Shiao, Khajeelak Chiablaem, Varodom Charoensawan, Nuttapong Ngamphaiboon, Natini Jinawath
Intrahepatic cholangiocarcinoma (ICC) is the cancer of the intrahepatic bile ducts, and together with hepatocellular carcinoma (HCC), constitute the majority of primary liver cancers. ICC is a rare disorder as its overall incidence is < 1/100,000 in the United States and Europe. However, it shows much higher incidence in particular geographical regions, such as northeastern Thailand, where liver fluke infection is the most common risk factor of ICC. Since the early stages of ICC are often asymptomatic, the patients are usually diagnosed at advanced stages with no effective treatments available, leading to the high mortality rate...
2018: Frontiers in Genetics
Cheng Lou, Tong Bai, Le-Wei Bi, Ying-Tang Gao, Zhi Du
AIM: To assess the impact of hepatitis B surface (HBsAg) seroclearance on survival outcomes in hepatitis B-related primary liver cancer. METHODS: Information from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved. Cases diagnosed with HBsAg (-) and HBcAb (+) liver cancer were included in the HBsAg seroclearance (SC) group. HBsAg (+) liver cancer patients strictly matched for liver cancer stage (AJCC staging system, 8th edition), Child-Pugh score, and first diagnosis/treatment method (surgery, ablation and TACE) were assigned to the HBsAg non-seroclearance (NSC) group...
August 16, 2018: World Journal of Clinical Cases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"